PMID- 35351121
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220402
IS  - 1472-6963 (Electronic)
IS  - 1472-6963 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Mar 29
TI  - Impact of proton pump inhibitor management committee's multifaceted interventions 
      on acid suppressant prescribing patterns in outpatient and emergency departments.
PG  - 417
LID - 10.1186/s12913-022-07820-x [doi]
LID - 417
AB  - BACKGROUND: A nationwide campaign for rational proton pump inhibitor (PPI) use 
      launched in 2015 had a positive impact for hospitalized patients PPI use. But 
      there were few studies focusing on the rational use of PPIs in outpatients. In 
      2018, the PPI management committee conducted a year-long intervention on the 
      appropriate use of PPIs in outpatient and emergency departments, including 
      clinical pharmacist interventions and stewardship interventions. The purpose of 
      this study was to examine the impact of the PPI management committee's 
      multifaceted interventions by comparing the real-world acid suppressant 
      prescribing patterns for outpatients before (2017) and after intervention (2019) 
      at a Chinese tertiary teaching hospital. METHODS: Prescriptions containing any 
      acid suppressant in outpatient and emergency departments in baseline (2017) and 
      postintervention (2019) periods were extracted from the hospital information 
      system and the prescription automatic screening system. Acid suppressant 
      prescribing patterns were evaluated based on primary diagnoses and patient 
      demographics. The prescribed acid suppressants stratified using age groups (< 7, 
      7-17, 18-45, 46-65, 66-85 and > 85 years) were also examined. RESULT: The 
      utilization rate of acid suppressant in 2017 and 2019 was 2.5% (41,165/1,619,366) 
      and 2.2% (49,550/2,236,471), respectively (P < 0.0001). 60,135 acid suppressant 
      prescriptions were obtained in 2017 and 73,275 in 2019. The rate of acid 
      suppressant prescriptions for the approved indications significantly increased 
      from 62.6% (2017) to 65.4% (2019) (P < 0.0001). Prescriptions diagnosed as 
      abnormal symptoms, signs and clinical manifestations, decreased in 2019 (13.0% 
      vs. 16.5%, P < 0.0001). The most frequently prescribed PPIs differed between 2017 
      and 2019 (rabeprazole 2017 vs. esomeprazole 2019). Omeprazole was the most common 
      PPI and cimetidine was the most common H(2)RA prescribed to patients 
      aged < 18 years in 2017 and 2019. A total of CNY11.83 million was spent on acid 
      suppressants in 2019, accounting for about 48.7% of total medication cost, 
      increased by 11.3% from 2017 (37.4%). CONCLUSION: The proportion of acid 
      suppressant prescriptions for approved indications was enhanced after the PPI 
      management committee's multifaceted interventions, but there were still some 
      problems in the selection of acid suppressants.
CI  - (c) 2022. The Author(s).
FAU - Liu, Lu
AU  - Liu L
AD  - Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, 
      No. 25 Taiping Street, Jiangyang District, Luzhou, 646000, China.
AD  - School of Pharmacy, Southwest Medical University, No.1 Xianglin Street, Longmatan 
      District, Luzhou, 646000, China.
FAU - Yu, Yongqi
AU  - Yu Y
AD  - Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, 
      No. 25 Taiping Street, Jiangyang District, Luzhou, 646000, China.
AD  - School of Pharmacy, Southwest Medical University, No.1 Xianglin Street, Longmatan 
      District, Luzhou, 646000, China.
FAU - Fan, Qingze
AU  - Fan Q
AD  - Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, 
      No. 25 Taiping Street, Jiangyang District, Luzhou, 646000, China.
FAU - Wu, Zhigui
AU  - Wu Z
AD  - Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, 
      No. 25 Taiping Street, Jiangyang District, Luzhou, 646000, China.
FAU - Li, Xiuying
AU  - Li X
AD  - Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, 
      No. 25 Taiping Street, Jiangyang District, Luzhou, 646000, China. 
      260554767@qq.com.
FAU - Luo, Hongli
AU  - Luo H
AD  - Department of Pharmacy, the Affiliated Hospital of Southwest Medical University, 
      No. 25 Taiping Street, Jiangyang District, Luzhou, 646000, China. 
      lyfylhl@163.com.
LA  - eng
PT  - Journal Article
DEP - 20220329
PL  - England
TA  - BMC Health Serv Res
JT  - BMC health services research
JID - 101088677
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Adolescent
MH  - Aged, 80 and over
MH  - Emergency Service, Hospital
MH  - Humans
MH  - Omeprazole/therapeutic use
MH  - *Outpatients
MH  - Pharmacists
MH  - *Proton Pump Inhibitors/therapeutic use
PMC - PMC8966235
OTO - NOTNLM
OT  - Acid suppressant
OT  - Histamine-2 receptor antagonist
OT  - Multifaceted intervention
OT  - Proton pump inhibitor
COIS- The authors declare that they have no competing interests.
EDAT- 2022/03/31 06:00
MHDA- 2022/04/01 06:00
PMCR- 2022/03/29
CRDT- 2022/03/30 05:37
PHST- 2021/12/06 00:00 [received]
PHST- 2022/03/17 00:00 [accepted]
PHST- 2022/03/30 05:37 [entrez]
PHST- 2022/03/31 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2022/03/29 00:00 [pmc-release]
AID - 10.1186/s12913-022-07820-x [pii]
AID - 7820 [pii]
AID - 10.1186/s12913-022-07820-x [doi]
PST - epublish
SO  - BMC Health Serv Res. 2022 Mar 29;22(1):417. doi: 10.1186/s12913-022-07820-x.